Bottom line
Is PILL a good fund? The bottom line
PILL is an actively managed leveraged & inverse ETF from Direxion.
It charges 0.98% — about $98 a year on every $10,000 invested, cheaper than 76% of leveraged & inverse funds we track.
It returned +75.0% over one year, −12.6% a year over five years (as of Dec 31, 2025, per its prospectus).
With $20.7 million in net assets and 73 holdings, its largest position is Goldman Financial (22.4%) and the top 10 make up 67.5% of the portfolio.
What stands out
- Low cost: cheaper than 76% of leveraged & inverse peers
What to watch
- Concentrated: top 10 holdings are 67.5% of assets
- Small fund ($20.7 million) — small funds are likelier to close
Updated Nov 19, 2026
What PILL invests in
The Fund seeks daily investment results, before fees and expenses, of 300% of the daily performance of the Index. The Fund does not seek to achieve its stated investment objective for a period of time different than a trading day.
"The Index is a modified equal-weighted index that is designed to measure performance of the stocks, defined as pharmaceutical and medical stocks, comprising the S&P Total Market Index that are classified in the Global Industry Classification Standard (GICS) pharmaceuticals sub-industry. To be eligible for inclusion in the Index, stocks must satisfy one of the following combined size and liquidity criteria: (1) have a float-adjusted market capitalization above $300 million with a float-adjusted liquidity ratio (defined by dollar value traded over the previous 12 months divided by the float-adjusted market capitalization as of the Index rebalancing reference date) above 50%; (2) have a float-adjusted market capitalization above $500 million with a float-adjusted liquidity ratio above 90%; or (3) have a float-adjusted market capitalization above $400 million with a float-adjusted…
From the fund's prospectus (filed Mar 3, 2026).
PILL performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| PILL | +75.0% | −12.6% | — |
| Leveraged & Inverse median | −7.7% | −11.8% | −13.5% |
Source: Fund prospectus, as of Dec 31, 2025
What PILL costs
On a $10,000 investment, PILL's 0.98% expense ratio costs about $98 a year. The prospectus estimates $1,456 in total costs over 10 years (assuming 5% annual returns). The median leveraged & inverse fund charges 1.31%.
PILL top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Goldman Financial | 22.36% |
| 2 | N/a | 16.36% |
| 3 | Dreyfus | 8.14% |
| 4 | N/a | 7.41% |
| 5 | Crinetics Pharmaceuticals In CRNX | 2.77% |
| 6 | Mbx Biosciences Inc MBX | 2.42% |
| 7 | Ataibeckley Inc ATAI UQ | 2.16% |
| 8 | Definium Therapeutics, Inc DFTX | 2.13% |
| 9 | Goldman Sachs Liq Es Fd A | 2.03% |
| 10 | Amylyx Pharmaceuticals Inc AMLX UW | 1.72% |
Source: SEC Form N-PORT, period ended Jul 31, 2026
The top 10 make up 67.5% of the fund. See all top 25 holdings and asset mix →